Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.
2.

Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.

Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF.

Mol Psychiatry. 1999 Nov;4(6):512-23. Review.

PMID:
10578232
3.

Schizophrenia as a disorder of neuroplasticity.

McCullumsmith RE, Clinton SM, Meador-Woodruff JH.

Int Rev Neurobiol. 2004;59:19-45. Review.

PMID:
15006483
4.

Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.

Keshavan MS.

J Psychiatr Res. 1999 Nov-Dec;33(6):513-21. Review.

PMID:
10628528
5.

Schizophrenia and glutamatergic transmission.

Tamminga CA.

Crit Rev Neurobiol. 1998;12(1-2):21-36. Review.

PMID:
9444480
6.

An integrated view of pathophysiological models of schizophrenia.

Duncan GE, Sheitman BB, Lieberman JA.

Brain Res Brain Res Rev. 1999 Apr;29(2-3):250-64. Review.

PMID:
10209235
7.

Neurochemistry and neuroendocrinology of schizophrenia: a selective review.

Lieberman JA, Koreen AR.

Schizophr Bull. 1993;19(2):371-429. Review.

PMID:
8100644
8.

The natural history and pathophysiology of treatment resistant schizophrenia.

Sheitman BB, Lieberman JA.

J Psychiatr Res. 1998 May-Aug;32(3-4):143-50. Review.

PMID:
9793867
9.

A critique of the dopamine hypothesis of schizophrenia and psychosis.

Moncrieff J.

Harv Rev Psychiatry. 2009;17(3):214-25. doi: 10.1080/10673220902979896. Review.

PMID:
19499420
10.

Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia.

Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris JG, Nagamoto HT, Olincy A, Ross RG, Stevens KE, Waldo M, Leonard S.

Am J Med Genet. 2000 Spring;97(1):58-64. Review.

PMID:
10813805
11.
12.

A GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia.

Caruncho HJ, Dopeso-Reyes IG, Loza MI, Rodríguez MA.

Crit Rev Neurobiol. 2004;16(1-2):25-32. Review.

PMID:
15581396
13.

The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.

Goto Y, Grace AA.

Int Rev Neurobiol. 2007;78:41-68. Review.

PMID:
17349857
14.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
15.

Stimulant-induced psychosis and schizophrenia: the role of sensitization.

Ujike H.

Curr Psychiatry Rep. 2002 Jun;4(3):177-84. Review.

PMID:
12003679
16.

The amphetamine-induced sensitized state as a model of schizophrenia.

Featherstone RE, Kapur S, Fletcher PJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1556-71. Epub 2007 Aug 28. Review.

PMID:
17884274
17.

Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.

du Bois TM, Huang XF.

Brain Res Rev. 2007 Feb;53(2):260-70. Epub 2006 Oct 2. Review.

PMID:
17014910
18.

Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis.

Wiescholleck V, Manahan-Vaughan D.

Neuropharmacology. 2013 Nov;74:48-58. doi: 10.1016/j.neuropharm.2013.01.001. Epub 2013 Jan 31. Review.

PMID:
23376021
19.

Schizophrenia: a neurodevelopmental perspective.

Pilowsky LS, Kerwin RW, Murray RM.

Neuropsychopharmacology. 1993 Aug;9(1):83-91. Review.

20.

The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity.

Pierce RC, Bari AA.

Rev Neurosci. 2001;12(2):95-110. Review.

PMID:
11392459

Supplemental Content

Support Center